OptimizeRx Q1 revenue up 22% to $13.7M; GAAP net loss widens to $3.8M

OptimizeRx Corp

2022-Q1 EPS reported -$0.21 revenue$13,731,530

Revenue $13.7M, +22% YoY; gross margin 59% vs 55%.
GAAP net loss $3.8M ($0.21 per share) vs loss $0.6M ($0.04) in Q1 2021.
Non-GAAP net loss $0.1M ($0.01 per share); cash $89.0M.
Reaffirmed FY2022 revenue guidance $80-85M (31-39% growth) and gross margin 57-60%.
Completed EvinceMed acquisition, a specialty drug prescription initiation platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.